Maravai LifeSciences Holdings Inc. Class A Common Stock vs SM Energy Company Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while SM Energy Company Common Stock trades at $38.17 (market cap $9.17B). The key difference: SM Energy Company Common Stock is far larger — about 9.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and SM Energy Company Common Stock pays a 2.28% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SM Energy Company Common Stock for 2 Days on average.
| MRVI | SM | |
|---|---|---|
Market Cap | $972.90M | $9.17B |
Volume | 4,325,710 | 2,026,791 |
Sector | Health | Energy |
52-Week High | $9.00 | $41.29 |
52-Week Low | $2.83 | $17.57 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $1.08B | $15.58B |
Dividend Yield | — | 2.28% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SM Energy (SM) trades at $38.54, up 2.26% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with a low P/E of 6.83, healthy profit margins above 19%, and positive cash flow generation. Recent analyst coverage remains overwhelmingly positive with 65% buy ratings and a $39.08 consensus target, slightly above current levels.
Outlook remains favorable given strong earnings momentum and attractive valuation metrics, though overbought RSI readings suggest near-term consolidation risk. The company's upcoming Q3 2026 earnings report on November 3rd represents the next key catalyst for price movement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →SM Energy is an independent oil and natural gas exploration and production company. Its operations include the Permian, Maverick, Uinta, and Denver-Julesburg basins.
Read more on SM →